Bone News and Research

RSS

Study reveals people with anorexia nervosa have increased fat content in their bone marrow

People with anorexia nervosa, paradoxically, have strikingly high levels of fat within their bone marrow, report researchers at Children's Hospital Boston. Their findings, based on MRI imaging of the knees of 20 girls with anorexia and 20 healthy girls of the same age, appear in the February issue of the Journal of Bone and Mineral Research.

9 Feb 2010

Genta commences Phase 2 trial of tesetaxel on first subject

Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta’s experience in melanoma clinical research.

9 Feb 2010

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.

8 Feb 2010

Beer may help prevent osteoporosis

A new study suggests that beer is a significant source of dietary silicon, a key ingredient for increasing bone mineral density. Researchers from the Department of Food Science & Technology at the University of California, Davis studied commercial beer production to determine the relationship between beer production methods and the resulting silicon content, concluding that beer is a rich source of dietary silicon. Details of this study are available in the February issue of the Journal of the Science of Food and Agriculture, published by Wiley-Blackwell on behalf of the Society of Chemical Industry.

8 Feb 2010

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine.

7 Feb 2010

Reliv International adds new products to its portfolio

Reliv International, Inc. introduced three new products to its Relivables line at the company's national conference here today. The products represent the first extension of the Relivables line since it was introduced last August.

6 Feb 2010

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

Gentium S.p.A. today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study," has been awarded the Van Bekkum Award for the best abstract submitted to the physician's program for the European Group for Blood and Marrow Transplantation's (EBMT) 36th Annual Meeting, to be held in Vienna, March 21-24, 2010.

5 Feb 2010

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

CORD:USE Cord Blood Bank and its program at South Miami Hospital are being featured on CNN en Espanol's show "Salud." This story on the importance of cord blood donation aired this week and can be seen Friday, February 5 at 9:30 a.m. EST and Sunday, February 7 at 9 a.m. EST and 3 p.m. EST on CNN en Espanol.

5 Feb 2010

Hope for back pain: Minimally invasive facet arthrodesis and spinal cord stimulation

Results from the first prospective study of minimally invasive facet arthrodesis and long-term data on spinal cord stimulation demonstrate the viability of these options to achieve pain relief in patients with various back pain conditions. The studies were presented today at the American Academy of Pain Medicine's 26th Annual Meeting in San Antonio, TX.

5 Feb 2010

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Hospital for Special Surgery, (HSS), a world leader in orthopedics and rheumatology, today announced its support of the Arthritis Foundation and Ad Council newly launched campaign, "Moving is the Best Medicine," to raise awareness of osteoarthritis, increase public health education and support breakthrough research.

5 Feb 2010

$AAOS issues new clinical practice guidelines for treating distal radius fractures$

AAOS issues new clinical practice guidelines for treating distal radius fractures

The American Academy of Orthopaedic Surgeons (AAOS) recently approved and released an evidence-based clinical practice guideline on the Treatment of Distal Radius Fractures.

5 Feb 2010

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Protalix Biotherapeutics, Inc. today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida.

5 Feb 2010

ThermoGenesis announces distribution agreement with GE Healthcare for its AXP System

ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, today announced a new enhanced distribution agreement with GE Healthcare, a unit of General Electric Company, for its AXP® AutoXpress ™ (AXP) System used in the processing of cord blood.

5 Feb 2010

NovaBone Products relocates operations division to expanded and upgraded facilities

NovaBone Products, LLC has announced the relocation of its operations division to expanded and upgraded facilities where it will meet increasing demands of higher sales to a more geographically diverse distributor network.

4 Feb 2010

New ‘smart coating’ enables safe surgical implants; prevents infections post surgery

Researchers at North Carolina State University have developed a "smart coating" that helps surgical implants bond more closely with bone and ward off infection.

4 Feb 2010

Study sheds new light on cancer metastasis

Some cells are natural rule-breakers. Neural crest cells for example, not only migrate throughout the body during development (most cells are more selective in their wandering), they are also more developmentally flexible than their predecessors (a no-no for nearly all cell types).

4 Feb 2010

Blood cytokine levels may help in predicting arthritic rheumatism

Levels of inflammatory proteins, so-called cytokines, are elevated in the blood even before the onset of arthritic rheumatism. This means that such blood samples could be used to predict the development of the disease and thereby make it possible to prevent the pathological process, according to an article by Umeå researcher Solbritt Rantapää-Dahlqvist and her associates in the journal Arthritis and Rheumatism.

4 Feb 2010

Researchers uncover new mechanism to protect individuals from serious complications of obesity

Although obesity is a risk factor for diabetes and coronary heart disease worldwide, only some obese individuals go on to develop these metabolic complications, while others are relatively protected. Defining these protective factors could help scientists prevent disease in the wider population.

4 Feb 2010

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.

4 Feb 2010

Bone News and Research

Study reveals people with anorexia nervosa have increased fat content in their bone marrow

Genta commences Phase 2 trial of tesetaxel on first subject

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

Beer may help prevent osteoporosis

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

Reliv International adds new products to its portfolio

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

News piece may highlight the importance of cord blood donation among Hispanic and Latino community

Hope for back pain: Minimally invasive facet arthrodesis and spinal cord stimulation

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

AAOS issues new clinical practice guidelines for treating distal radius fractures

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

ThermoGenesis announces distribution agreement with GE Healthcare for its AXP System

NovaBone Products relocates operations division to expanded and upgraded facilities

New ‘smart coating’ enables safe surgical implants; prevents infections post surgery

Study sheds new light on cancer metastasis

Blood cytokine levels may help in predicting arthritic rheumatism

Researchers uncover new mechanism to protect individuals from serious complications of obesity

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News